**10th Annual Pulmonary Hypertension Symposium The Long and Winding Road: The Continued Mission to Raise Awareness and Educate Our Region on Pulmonary Hypertension**

**November 11, 2023**

**8:00 AM – 1:00 PM**

**EVMS**

**Target Audience**

Physician, Allied Health Professional, Nurse, Nurse Practitioner, Pharmacist, Physician Assistant, Resident, Student, Fellow

**Specialties**

Internal Medicine, Critical Care Medicine, Pulmonary Disease, Pccm

**Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

1 Identify signs, symptoms, and risk factors associated with PAH to facilitate timely referral of patients.

1 Articulate diagnostic tests used to identify patients with PAH.

2 Design a more rapid and multidisciplinary approach to earlier detection of PAH.

3 Appraise future advancements of care in pulmonary hypertension.

4 Describe the pharmacologic management of PAH patients.

**Accreditation**

Sentara is accredited by the Medical Society of Virginia (MSV) to provide medical education for physicians.

Sentara designates this Live Activity for a maximum of 4.50 *AMA PRA Category 1 Credit(s)TM*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians may claim up to 4.50 credits in Type 1 or Type 2 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for the renewal of an active medical license.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

**Acknowledgement of Educational Grant and/or Commercial Support**

None

**HIPAA**

Please comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

### Mitigation of Relevant Financial Relationships

Sentara adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible companies.

All relevant financial disclosures with ineligible companies have been mitigated prior to the commencement of the activity.

The following relationships have been reported for this activity:

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Amy Ross, BS, RCIS | Activity Coordinator | Nothing to disclose - 11/02/2023 |
| Deborah Levine, MD | Faculty | Nothing to disclose - 11/10/2023 |
| Edward J Sawey, MD, FACC | Faculty | Nothing to disclose - 09/22/2023 |
| Michael Eggert, MD | Course Director, Faculty | Grant or research support-Merck (Any division)|Grant or research support-United Therapeutics - 11/10/2023 |
| Jean Elwing, MD | Faculty | Consulting Fee-United Therapeutics|Consulting Fee-Altavant|Consulting Fee-Aerovate|Consulting Fee-Bayer (Any division)|Consulting Fee-Gossamer Bio|Consulting Fee-Liquida|Consulting Fee-Merck (Any division)|Grant or research support-Janssen (Any division)|Grant or research support-United Therapeutics|Grant or research support-Liquida|Grant or research support-Phase Bio|Grant or research support-Gossamer Bio|Grant or research support-Bayer (Any division)|Grant or research support-Acceleron|Grant or research support-Altavant|Grant or research support-Aerovate|Grant or research support-Tenax|Grant or research support-Pharmosa - 11/10/2023 |
| Matthew Bernens, MD | Faculty | Nothing to disclose - 11/10/2023 |
| VIkramjit Khangoora, MD | Faculty | Nothing to disclose - 11/10/2023 |

None of the other faculty, planners, or reviewers for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.